A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer (0683-008)

Status:
Completed

Trial end date:
2005-11-01

Target enrollment:

Participant gender:

This study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MK0683 in patients with advanced cancer.

Phase 1

Merck Sharp & Dohme Corp.

Vorinostat